Paget's disease of the skull causing hyperprolactinemia and erectile dysfunction: a case report
© Hepherd and Jennings; licensee BioMed Central Ltd. 2008
Received: 12 October 2007
Accepted: 18 July 2008
Published: 18 July 2008
Hyperprolactinemia is an uncommon cause of erectile dysfunction in men. Paget's disease of the skull is a relatively common disease. This case proposes a rare example of a causative link between the two and how treatment of the Paget's disease with bisphosphonates helped the patient regain erectile function.
A 67-year-old man with Paget's disease of the skull presented with prostatitis, erectile dysfunction, and hyperprolactinemia. Radio-isotope scanning showed increased vascularity around the sphenoid bone. Treatment with intravenous bisphosphonates improved the active Paget's disease as indicated by declining alkaline phosphatase levels and the patient's erectile function while serum prolactin levels became normal and serum testosterone levels remained unchanged.
It is possible that hyperprolactinemia is unrecognised in other patients with Paget's disease of the skull. Normalizing elevated prolactin levels by using bisphosphonates in treating Paget's disease appears to be more appropriate than traditional treatment for hyperprolactinemia.
We describe the case of a man who presented with erectile dysfunction secondary to hyperprolactinemia, an uncommon cause of erectile dysfunction in men. In addition, we discuss how the hyperprolactinemia arose, due to Paget's disease of the skull, which caused increased vascularity around the sphenoid bone, as proven by radio-isotope scanning.
A 67-year-old man presented with recurrent renal calculi and prostatitis. During the course of the consultation, he also complained of erectile dysfunction. Subsequent biochemical investigations revealed a raised level of prolactin and he was referred to the endocrinology department.
Initial biochemical investigations
After 24 months
2.10 to 2.60 mmol/litre
30 to 110 IU/litre
Follicle stimulating hormone
1.0 to 7.0 IU/litre
1.0 to 8.0 IU/litre
10.0 to 31.0 nmol/litre
33 to 585 mU/litre
Thyroid stimulating hormone
0.1 to 5.0 mU/litre
10 to 24 mmol/litre
The pituitary gland appeared normal on sagittal and coronal reconstructions therefore, the patient underwent a radio-isotope bone scan. This revealed increased bone activity within the skull vault, with further areas in the left petrous temporal bone and extending into the skull base in the region of the pituitary fossa.
The hypothesis was that the hyperprolactinaemia may have been consequent upon the increased vascularity and blood flow through the sphenoid secondary to the activity of the Paget's disease. The patient was treated with intravenous pamidronate (30 mg per week over 6 weeks) and both alkaline phosphatase and prolactin levels became normal, while the patient regained erectile function.
Causes and risk factors for erectile dysfunction 
Spinal cord injury
Blunt perineal and/or pelvic trauma
Hyperprolactinemia is a relatively uncommon cause of erectile dysfunction in men and is most often caused by a microprolactinoma of the pituitary gland. Symptoms may also include diminished libido, infertility and more rarely, reduction in facial and body hair, galactorrhoea and gynaecomastia . Prolactin inhibits the release of LH and FSH, directly impairing testosterone production . Treatment of hyperprolactinemia/prolactinoma is via suppression of prolactin, either with medical therapy using dopamine agonists (eg bromocriptine or cabergoline) or transsphenoidal surgery [4, 5]. Prolactin secretion is normally inhibited by dopamine flux down the pituitary stalk from the hypothalamus. Raised prolactin levels occur due to either a prolactin-secreting adenoma within the pituitary or from the lack of dopamine-mediated suppression from stalk dysfunction, which can occur if the stalk is distorted by intra- or extra-sella lesions, as we believe was the case in this patient. In this case, conventional treatment for hyperprolactinaemia would only be symptomatic, given that the underlying cause was not due to a prolactin-secreting tumour, but to the increased vascularity of the bones and associated deformity surrounding the pituitary gland, along with stalk dysfunction.
The response to treatment of hyperprolactinemia/prolactinoma is via measurement of normalizing prolactin, along with subjective improvement of symptoms, such as return of libido or erectile function .
Paget's disease of bone (osteitis deformans) is a chronic inflammatory remodelling disease first described by Sir James Paget in 1877 . Any bone may be affected but most commonly it is the axial skeleton (spine, pelvis, femur, sacrum and skull) that is affected. The symptoms of Paget's disease include bone pain, skeletal deformity, pathological fractures and high-output congestive cardiac failure (increased vascularity and blood flow). Symptoms and complications in the skull include headache, skull enlargement (for example, frontal bossing) and deafness owing to compression of the eighth cranial nerve. More rarely, compression of the second, fifth and seventh cranial nerves can occur, if the disease directly disrupts the paths of these nerves [7, 8].
The mainstay of treatment for Paget's disease is to control disease activity with bisphosphonates. This is the first reported case of Paget's disease affecting pituitary gland function by involvement of the sphenoid bone. In this case, a course of intravenous pamidronate was used successfully but other oral bisphosphonates can be used depending on disease severity [7, 8].
Hyperprolactinemia is an extremely rare consequence of a common bone disorder. Although there are other complications of Paget's disease related to increased vascularity of bone, we have not identified any such similar cases of pituitary hormone dysfunction in the literature. This complication was important to recognise as hyperprolactinemia was treated by treating the Paget's disease with bisphosphonates, and not with traditional therapies used for hyperprolactinemia/microprolactinoma.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- McVary KT: Clinical practice. Erectile dysfunction. N Engl J Med. 357 (24): 2472-81. 10.1056/NEJMcp067261. 2007 Dec 13;View ArticlePubMedGoogle Scholar
- Bhasin S, Cunningham GR, Hayes FJ: Testosterone therapy in adult men with testosterone deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006, 91 (6): 1995-2010. 10.1210/jc.2005-2847.View ArticlePubMedGoogle Scholar
- Morgentaler A: Male impotence. Lancet. 1999, 354: 1713-1718. 10.1016/S0140-6736(99)06586-1.View ArticlePubMedGoogle Scholar
- Jones TH: The management of hyperprolactinaemia. Br J Hosp Med. 1995, 53: 374-378.PubMedGoogle Scholar
- Mancini T, Casanueva FF, Giustiana A: Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008, 37 (1): 67-99. 10.1016/j.ecl.2007.10.013.View ArticlePubMedGoogle Scholar
- Paget J: On a form of chronic inflammation of bones (osteitis deformans). Medico-Chirurgical Transactions, London. 1877, 60: 37-63.Google Scholar
- Paget Disease. http://www.emedicine.com/med/topic2998.htm
- Roodman GD, Windle JJ: Paget disease of bone. J Clin Invest. 2005, 115: 200-208.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.